+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of slow oxprenolol and a combination of slow oxprenolol and cyclopenthiazide on plasma lipoproteins



Effect of slow oxprenolol and a combination of slow oxprenolol and cyclopenthiazide on plasma lipoproteins



Atherosclerosis 39(3): 301-306



The effect of slow oxprenolol on plasma lipoprotein concentrations was compared to that of combined therapy with slow oxprenolol and cyclopenthiazide. The design of the study was a double blind between patient investigation in which 9 subjects with mild hypertension received slow oxprenolol and 11 slow oxprenolol and cyclopenthiazide. Plasma lipoproteins were analysed at 0, 2, 4, 8, 12 and 16 weeks. Slow oxprenolol given alone resulted in a significant rise in plasma and low density lipoprotein (LDL) cholesterol concentration whereas combined therapy with slow oxprenolol and cyclopenthiazide produced significant rises in plasma and very low density lipoprotein (VLDL) triglyceride. If one accepts that a rise in plasma or LDL cholesterol increases atherogenic risk more than a rise in plasma or VLDL triglyceride combined therapy is preferable.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 042929269

Download citation: RISBibTeXText

PMID: 7259814

DOI: 10.1016/0021-9150(81)90016-2


Related references

A comparison of slow Trasicor (oxprenolol 160 mg) and Trasidrex (oxprenolol 160 mg and cyclopenthiazide 0.25 mg) in the treatment of hypertension in general practice. Journal of International Medical Research 9(5): 315-318, 1981

Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation. British Journal of Clinical Pharmacology 12(6): 869-871, 1981

Comparison of the activity and plasma levels of oxprenolol slow release oxprenolol long acting propranolol and sotalol. European Journal of Clinical Pharmacology 17(6): 419-424, 1980

Oxprenolol slow-release with cyclopenthiazide KCl in the treatment of essential hypertension. A multicentre general practice study. South African Medical Journal 59(25): 893-899, 1981

Comparison of a slow-release formulation of oxprenolol with conventional oxprenolol in the treatment of hypertension. Clinical Science and Molecular Medicine. Supplement 3: 559s-561s, 1976

A comparison of slow release oxprenolol with conventional oxprenolol in the treatment of hypertension. European Journal of Clinical Pharmacology 14(2): 77-82, 1978

Slow-release oxprenolol compared with oxprenolol in hypertensive patients: a multicenter clinical trial. Drug Intelligence and Clinical Pharmacy 17(1): 51-54, 1983

Long-term treatment with slow release oxprenolol alone, or in combination with other drugs: effects on blood pressure, lipoproteins and exercise performance. Australian and New Zealand Journal of Medicine 12(6): 612-616, 1982

Oxprenolol slow-release with cyclopenthiazide-KCl compared with methyldopa in the treatment of essential hypertension. A multicentre general practice trial. South African Medical Journal 54(21): 860-864, 1978

Slow release oxprenolol in angina pectoris: study comparing oxprenolol, once daily, with propranolol, four times daily. American Journal of Cardiology 47(5): 1123-1127, 1981

Comparison of clinical effects of propranolol (Inderal) with once daily slow-release oxprenolol (Slow Trasicor) in angina pectoris. Journal of International Medical Research 7(3): 194-200, 1979

A fixed combination of oxprenolol slow-release and chlorthalidone once daily in treatment of mild to moderate hypertension. International Journal of Clinical Pharmacology, Therapy, and Toxicology 19(6): 249-255, 1981

A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects. British Journal of Clinical Pharmacology 3(3): 439-443, 1976

One year efficacy and tolerability of oxprenolol slow-release and chlorthalidone on fixed combination in mild to moderate hypertension. Giornale Italiano di Cardiologia 11(12): 2105-2109, 1981

Antihypertensive effect of a new formulation of slow release oxprenolol in essential hypertension. Journal of Cardiovascular Pharmacology 10(5): 593-598, 1987